• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CRISPR/Cas9基因编辑在B细胞淋巴瘤中的应用与进展：一项叙述性综述

Application and progress of CRISPR/Cas9 gene editing in B-cell lymphoma: a narrative review.

作者信息

Jin Ying, Wu Haiyi, Liu Jianzhao, Cho William C, Song Guoqi

机构信息

Department of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.

Department of Hematology, Affiliated Hospital of Nantong University, Dalian Medical University, Dalian, China.

出版信息

Transl Cancer Res. 2024 Mar 31;13(3):1584-1595. doi: 10.21037/tcr-23-1146. Epub 2024 Mar 14.

DOI:10.21037/tcr-23-1146
PMID:38617522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11009809/
Abstract

BACKGROUND AND OBJECTIVE

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) gene editing and CRISPR/Cas9 screening libraries are hot topics, and have high application values in the diagnosis and treatment of genetic diseases, and the improvement of prognosis. The major treatment of B-cell lymphoma is chemotherapy combined with biological therapy. Due to the individual specificity and the emergence of drug resistance, the therapeutic efficacy varies. The objective of this article is to explore potential targets to enhance therapeutic effects, optimize treatment plans, and improve the prognosis of patients with B-cell lymphoma.

METHODS

We undertook a comprehensive, narrative review of the latest literature to define the current application and progress of CRISPR/Cas9 in B-cell lymphoma.

KEY CONTENT AND FINDINGS

The concepts of CRISPR/Cas9, the mechanism of gene editing, and the procedures of CRISPR/Cas9 screening libraries are investigated for candidate genes. We mainly focus on application and progress of CRISPR/Cas9 in B-cell lymphoma and screen out some genes, signaling pathways, and cytokines, which may become potential targets for clinical treatment.

CONCLUSIONS

CRISPR/Cas9 gene editing has great promise in the treatment of B-cell lymphoma. This article reviews some genes, signaling pathways, and cytokines related to the progression and prognosis of B-cell lymphoma to provide a strong theoretical basis.

摘要

背景与目的

成簇规律间隔短回文重复序列（CRISPR）/CRISPR相关蛋白9（Cas9）基因编辑及CRISPR/Cas9筛选文库是热门话题，在遗传病的诊断与治疗以及改善预后方面具有很高的应用价值。B细胞淋巴瘤的主要治疗方法是化疗联合生物治疗。由于个体特异性和耐药性的出现，治疗效果各不相同。本文的目的是探索增强治疗效果、优化治疗方案以及改善B细胞淋巴瘤患者预后的潜在靶点。

方法

我们对最新文献进行了全面的叙述性综述，以确定CRISPR/Cas9在B细胞淋巴瘤中的当前应用和进展。

关键内容与发现

研究了CRISPR/Cas9的概念、基因编辑机制以及CRISPR/Cas9筛选文库用于候选基因的流程。我们主要关注CRISPR/Cas9在B细胞淋巴瘤中的应用和进展，并筛选出一些可能成为临床治疗潜在靶点的基因、信号通路和细胞因子。

结论

CRISPR/Cas9基因编辑在B细胞淋巴瘤治疗中具有巨大潜力。本文综述了一些与B细胞淋巴瘤进展和预后相关的基因、信号通路和细胞因子，以提供有力的理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddba/11009809/e1059dac353e/tcr-13-03-1584-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddba/11009809/bb6e163dd612/tcr-13-03-1584-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddba/11009809/e1059dac353e/tcr-13-03-1584-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddba/11009809/bb6e163dd612/tcr-13-03-1584-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddba/11009809/e1059dac353e/tcr-13-03-1584-f2.jpg

相似文献

1
Application and progress of CRISPR/Cas9 gene editing in B-cell lymphoma: a narrative review.CRISPR/Cas9基因编辑在B细胞淋巴瘤中的应用与进展：一项叙述性综述
Transl Cancer Res. 2024 Mar 31;13(3):1584-1595. doi: 10.21037/tcr-23-1146. Epub 2024 Mar 14.
2
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review.利用CRISPR-Cas9技术克服肺癌治疗中耐药性的研究：一项叙述性综述。
Transl Lung Cancer Res. 2024 Aug 31;13(8):2067-2081. doi: 10.21037/tlcr-24-592. Epub 2024 Aug 28.
3
Clustered Regularly Interspaced Short Palindromic Repeats and Clustered Regularly Interspaced Short Palindromic Repeats-Associated Protein 9 System: Factors Affecting Precision Gene Editing Efficiency and Optimization Strategies.成簇规律间隔短回文重复序列和成簇规律间隔短回文重复序列相关蛋白 9 系统：影响精确基因编辑效率的因素和优化策略。
Hum Gene Ther. 2023 Dec;34(23-24):1190-1203. doi: 10.1089/hum.2023.115. Epub 2023 Oct 17.
4
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.利用 CRISPR/Cas9 技术编辑 B 淋巴瘤细胞系中的基因。
Methods Mol Biol. 2020;2115:445-454. doi: 10.1007/978-1-0716-0290-4_25.
5
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.CRISPR/Cas9 基因编辑在癌症中的当前应用和未来展望。
Mol Cancer. 2022 Feb 21;21(1):57. doi: 10.1186/s12943-022-01518-8.
6
CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.CRISPR-Cas9，癌症治疗有前途的治疗工具：综述。
Protein Pept Lett. 2020;27(10):931-944. doi: 10.2174/0929866527666200407112432.
7
Applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) as a Genetic Scalpel for the Treatment of Cancer: A Translational Narrative Review.成簇规律间隔短回文重复序列（CRISPR）作为治疗癌症的基因手术刀的应用：一项转化性叙述性综述
Cureus. 2023 Dec 6;15(12):e50031. doi: 10.7759/cureus.50031. eCollection 2023 Dec.
8
Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.CRISPR/Cas9 基因编辑技术在癌症治疗研究中的应用。
Clin Genet. 2020 Jan;97(1):73-88. doi: 10.1111/cge.13589. Epub 2019 Jul 10.
9
[Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].成簇规律间隔短回文重复序列（CRISPR）/CRISPR相关蛋白9系统在干细胞研究中的应用进展
Zhonghua Shao Shang Za Zhi. 2018 Apr 20;34(4):253-256. doi: 10.3760/cma.j.issn.1009-2587.2018.04.013.
10
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy.CRISPR/Cas9 基因组编辑在基因治疗中的临床应用的潜力与承诺。
J Adv Res. 2022 Sep;40:135-152. doi: 10.1016/j.jare.2021.11.018. Epub 2021 Dec 4.

引用本文的文献

1
Cleavage efficiency of CRISPR/Cas9 system with G-quadruplex-capped single-guide RNA motifs in RNase II and RNase R.具有G-四链体封端单导向RNA基序的CRISPR/Cas9系统在核糖核酸酶II和核糖核酸酶R中的切割效率
3 Biotech. 2025 Jun;15(6):189. doi: 10.1007/s13205-025-04354-x. Epub 2025 May 26.

本文引用的文献

1
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.靶向 PD-1 和 LAG-3 的双特异性分子替西利珠单抗治疗实体瘤和血液系统恶性肿瘤的 1 期临床试验。
Nat Med. 2023 Nov;29(11):2814-2824. doi: 10.1038/s41591-023-02593-0. Epub 2023 Oct 19.
2
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.抑制性共受体 CTLA-4 的缺失增强并激活嵌合抗原受体 T 细胞。
Immunity. 2023 Oct 10;56(10):2388-2407.e9. doi: 10.1016/j.immuni.2023.09.001. Epub 2023 Sep 29.
3
Dimethyl fumarate inhibits necroptosis and alleviates systemic inflammatory response syndrome by blocking the RIPK1-RIPK3-MLKL axis.
富马酸二甲酯通过阻断RIPK1-RIPK3-MLKL轴抑制坏死性凋亡并减轻全身炎症反应综合征。
Pharmacol Res. 2023 Mar;189:106697. doi: 10.1016/j.phrs.2023.106697. Epub 2023 Feb 14.
4
Author Correction: Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.作者更正：超级增强子超突变改变B细胞淋巴瘤中的癌基因表达。
Nature. 2022 Nov;611(7934):E2. doi: 10.1038/s41586-022-05285-w.
5
Author Correction: DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression.作者更正：DNA甲基化酶和PRC1限制B细胞爱泼斯坦-巴尔病毒癌蛋白表达。
Nat Microbiol. 2022 Jun;7(6):928. doi: 10.1038/s41564-022-01137-5.
6
Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function.设计和评估 TIM-3-CD28 检查点融合蛋白以改善抗 CD19 CAR T 细胞功能。
Front Immunol. 2022 Apr 6;13:845499. doi: 10.3389/fimmu.2022.845499. eCollection 2022.
7
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion.环境与自然资源部控制 JAK2 的翻译以诱导 PD-L1 的表达，从而实现肿瘤免疫逃逸。
Nat Commun. 2022 Apr 19;13(1):2059. doi: 10.1038/s41467-022-29754-y.
8
Spacer prioritization in CRISPR-Cas9 immunity is enabled by the leader RNA.间隔区在 CRISPR-Cas9 免疫中的优先级由前导 RNA 决定。
Nat Microbiol. 2022 Apr;7(4):530-541. doi: 10.1038/s41564-022-01074-3. Epub 2022 Mar 21.
9
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.双重 BTK/SYK 抑制联合 CG-806（芦可替尼）可破坏套细胞淋巴瘤中 B 细胞受体和 Bcl-2 信号网络。
Cell Death Dis. 2022 Mar 16;13(3):246. doi: 10.1038/s41419-022-04684-1.
10
CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.CRISPR-Cas9 基因治疗杜氏肌营养不良症。
Neurotherapeutics. 2022 Apr;19(3):931-941. doi: 10.1007/s13311-022-01197-9. Epub 2022 Feb 14.